Profile data is unavailable for this security.
About the company
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), which is an N-methyl-D-aspartate (NMDA) receptor antagonist. The Company’s lead product candidate, esmethadone, is a new chemical entity (NCE) developed as a rapidly acting, oral agent for the treatment of depression, central nervous system (CNS) diseases and other potential indications. The Company’s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission and is in development for both the adjunctive or monotherapy treatment of major depressive disorder (MDD).
- Revenue in USD (TTM)0.00
- Net income in USD-153.48m
- Incorporated2012
- Employees10.00
- LocationRelmada Therapeutics Inc2222 Ponce De Leon Blvd. 3Rd FloorCORAL GABLES 33134United StatesUSA
- Phone+1 (646) 876-3459
- Websitehttps://www.relmada.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Omeros Corporation | -21.06m | -197.97m | 134.24m | 213.00 | -- | -- | -- | -- | -3.16 | 3.21 | -0.3363 | -0.7395 | -0.0725 | -- | -- | -98,877.94 | -68.15 | -89.49 | -79.40 | -118.59 | -- | 98.32 | -- | -731.08 | -- | -9.15 | 1.12 | -- | -- | -- | -10.64 | -- | 17.06 | -- |
| VBI Vaccines Inc | 870.00k | -110.95m | 134.29m | 149.00 | -- | 1.60 | -- | 154.36 | -0.4298 | -0.4298 | 0.0034 | 0.3246 | 0.0044 | 2.78 | 10.36 | 5,838.93 | -56.00 | -35.40 | -67.52 | -40.89 | -1,188.16 | -361.63 | -12,752.30 | -3,361.50 | 2.61 | -2.75 | 0.3662 | -- | -40.53 | 2.86 | -50.88 | -- | 27.81 | -- |
| Cue Biopharma Inc | 9.35m | -46.80m | 136.59m | 57.00 | -- | 2.69 | -- | 14.61 | -1.38 | -1.38 | 0.2763 | 1.43 | 0.1205 | -- | 11.93 | 164,006.50 | -60.32 | -56.36 | -72.23 | -65.49 | -- | -- | -500.65 | -827.70 | -- | -- | 0.164 | -- | 373.68 | -- | 1.39 | -- | 12.09 | -- |
| VolitionRX Ltd | 200.91k | -31.06m | 136.90m | 83.00 | -- | 41.50 | -- | 681.40 | -0.5721 | -0.5721 | 0.0037 | 0.0574 | 0.0075 | -- | 16.03 | 2,420.60 | -117.61 | -91.10 | -201.60 | -110.87 | -- | -- | -15,614.21 | -79,842.38 | -- | -351.22 | 0.5973 | -- | 570.44 | -- | -31.75 | -- | 18.59 | -- |
| Larimar Therapeutics Inc | 0.00 | -35.06m | 137.16m | 31.00 | -- | 1.16 | -- | -- | -1.83 | -1.83 | 0.00 | 2.74 | 0.00 | -- | -- | 0.00 | -31.74 | -48.65 | -34.85 | -53.98 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -19.19 | -- | -12.79 | -- |
| Alaunos Therapeutics Inc | 2.91m | -40.37m | 137.92m | 41.00 | -- | 4.29 | -- | 47.38 | -0.1878 | -0.1878 | 0.0135 | 0.1486 | 0.0322 | -- | 1.32 | 71,000.00 | -44.58 | -68.97 | -67.24 | -80.06 | -- | -- | -1,386.64 | -5,538.19 | -- | -12.33 | 0.4138 | -- | -- | -43.42 | 1.53 | -- | 43.24 | -- |
| Taysha Gene Therapies Inc | 0.00 | -160.68m | 138.00m | 178.00 | -- | 8.18 | -- | -- | -4.12 | -4.12 | 0.00 | 0.2702 | 0.00 | -- | -- | 0.00 | -91.16 | -- | -116.37 | -- | -- | -- | -- | -- | -- | -43.46 | 0.7725 | -- | -- | -- | -190.82 | -- | -- | -- |
| Relmada Therapeutics Inc | 0.00 | -153.48m | 139.96m | 10.00 | -- | 0.8007 | -- | -- | -5.85 | -5.85 | 0.00 | 5.81 | 0.00 | -- | -- | 0.00 | -110.39 | -- | -128.42 | -- | -- | -- | -- | -- | -- | -50.56 | 0.00 | -- | -- | -- | -111.50 | -- | -- | -- |
| Celcuity Inc | 0.00 | -35.54m | 141.30m | 39.00 | -- | 3.14 | -- | -- | -2.38 | -2.38 | 0.00 | 2.91 | 0.00 | -- | -- | 0.00 | -45.24 | -44.12 | -48.14 | -45.72 | -- | -- | -- | -- | -- | -23.19 | 0.2565 | -- | -- | -- | -212.48 | -- | 14.90 | -- |
| ORIC Pharmaceuticals Inc | 0.00 | -91.05m | 142.08m | 88.00 | -- | 0.6614 | -- | -- | -2.31 | -2.31 | 0.00 | 5.43 | 0.00 | -- | -- | 0.00 | -32.98 | -- | -34.55 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -6.80 | -- | -- | -- |
| Mallinckrodt PLC | 2.02bn | -867.10m | 142.58m | 2.80k | -- | 0.0771 | -- | 0.0705 | -44.95 | -44.89 | 41.31 | 140.39 | 0.2624 | 2.07 | 5.00 | 722,214.30 | -11.25 | -8.61 | -13.71 | -10.21 | 26.18 | 45.66 | -42.88 | -34.46 | 1.41 | -0.5702 | 0.6247 | -- | -19.66 | -- | 25.39 | -- | -- | -- |
| RVL Pharmaceuticals PLC | 42.77m | -53.05m | 142.78m | 156.00 | -- | 2.08 | -- | 3.34 | -0.6251 | -0.6257 | 0.5020 | 0.6913 | 0.3229 | 11.04 | 15.39 | 274,192.30 | -40.05 | -18.78 | -55.99 | -21.86 | 81.35 | 51.85 | -124.02 | -61.82 | 3.27 | -90.10 | 0.4493 | -- | -90.16 | -39.64 | -4.10 | -- | -35.47 | -- |
| Matinas BioPharma Holdings Inc | 2.13m | -24.06m | 143.13m | 31.00 | -- | 3.71 | -- | 67.36 | -0.111 | -0.111 | 0.0098 | 0.1781 | 0.0371 | -- | -- | 68,548.39 | -42.02 | -51.16 | -45.60 | -55.50 | -- | -- | -1,132.32 | -16,821.71 | -- | -- | 0.0002 | -- | -78.95 | -- | -1.89 | -- | -- | -- |
| LAVA Therapeutics NV | 17.46m | -26.53m | 144.85m | 55.00 | -- | 1.53 | -- | 8.30 | -1.54 | -1.54 | 0.7144 | 3.59 | 0.1161 | -- | -- | 317,487.40 | -17.64 | -- | -18.77 | -- | -- | -- | -151.91 | -- | -- | -- | 0.0476 | -- | 42.86 | -- | -192.45 | -- | -- | -- |
| Artemis Therapeutics Inc | 195.00k | -890.00k | 145.64m | 13.00 | -- | -- | -- | 746.89 | -0.0284 | -0.0284 | 0.0065 | -0.0059 | 0.9899 | -- | -- | -- | -455.33 | -182.34 | -- | -- | 87.18 | -- | -460.00 | -- | 0.2201 | -- | -- | -- | -- | -- | -37.86 | -- | -- | -- |
| Singular Genomics Systems Inc | 0.00 | -89.54m | 145.65m | 269.00 | -- | 0.5253 | -- | -- | -1.26 | -1.26 | 0.00 | 3.88 | 0.00 | -- | -- | 0.00 | -25.00 | -- | -25.72 | -- | -- | -- | -- | -- | 19.00 | -- | 0.0349 | -- | -- | -- | -253.45 | -- | -- | -- |
Data as of Nov 30 2022. Currency figures normalised to Relmada Therapeutics Inc's reporting currency: US Dollar USD
62.48%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RTW Investments LPas of 30 Sep 2022 | 2.64m | 8.80% |
| Deep Track Capital LPas of 13 Oct 2022 | 2.48m | 8.25% |
| Perceptive Advisors LLCas of 30 Sep 2022 | 2.38m | 7.93% |
| BVF Partners LPas of 30 Sep 2022 | 2.08m | 6.91% |
| Point72 Asset Management LPas of 13 Oct 2022 | 2.03m | 6.76% |
| RA Capital Management LPas of 30 Sep 2022 | 2.00m | 6.65% |
| BlackRock Fund Advisorsas of 30 Sep 2022 | 1.85m | 6.16% |
| The Vanguard Group, Inc.as of 30 Sep 2022 | 1.39m | 4.61% |
| Citadel Advisors LLCas of 07 Oct 2022 | 1.33m | 4.44% |
| SSgA Funds Management, Inc.as of 30 Sep 2022 | 590.13k | 1.96% |
More ▼
Data from 30 Sep 2022 - 30 Sep 2022Source: FactSet Research Systems Inc.
